Eli Lilly claims that it's finally producing enough of its weight loss drugs. Companies producing substitutes for those drugs may have trouble growing soon.
Lilly's Mounjaro and Zepbound are only warming up. The company has several other promising drugs in its lineup and pipeline.
As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.
Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.
James Shin, Deutsche Bank analyst, joins 'Closing Bell Overtime' to talk its big Eli Lilly upgrade.
While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation
Scott Nations, Nations Indexes president, joins 'Power Lunch' to discuss stock plays for three stocks.

Eli Lilly (LLY), A.I. and State of the Mag 7

04:22pm, Monday, 12'th Aug 2024
Sylvia Jablonski with Defiance ETFs says she doesn't think "the macro market has changed," even after last week's turbulent market action. She joins Oliver Renick to share why Eli Lilly (LLY) "continu
Fund managers have been busy buying amid the ongoing market weakness. Four stocks are near buy points or are building bases.
Deutsche Bank is out with a bullish call on Eli Lilly (LLY), raising its rating on the pharma stock from Hold to Buy and lifting its price target by $300 to a total of $1,025 a share. Deutsche Bank An
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
Eli Lilly and Company reported strong Q2 2024 earnings with revenues up 36% year-on-year, exceeding expectations. Guidance for 2024 was raised by ~$3bn with expectations of $45.4bn — $46.6bn in reve
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Is Eli Lilly a Stock To Buy and Hold Forever?

10:15am, Monday, 12'th Aug 2024
Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE